FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103292074> ?p ?o ?g. }

• W2103292074 endingPage "647" @default.
• W2103292074 startingPage "641" @default.
• W2103292074 abstract "Hospitalization for acute decompensated heart failure (ADHF) involves substantial morbidity and mortality. Current management strategies have major limitations, and there has been little progress in the development of newer therapies. Arginine vasopressin-receptor antagonists may have promise in the treatment of ADHF in view of their ability to facilitate diuresis. This pilot study was designed to evaluate the efficacy and safety of intravenous conivaptan, a dual arginine vasopressin V(1A)/V(2)-receptor antagonist, in treating ADHF.In a double-blind, multicenter trial, 170 patients hospitalized for worsening heart failure and given standard therapy were randomly assigned to treatment with conivaptan (20-mg loading dose followed by 2 successive 24-hour continuous infusions of 40, 80, or 120 mg/d) or placebo. The conivaptan and placebo groups did not differ significantly in patient or clinician assessments of global and respiratory status at 48 hours. There was no evidence of worsening heart failure in any group. Conivaptan at each dosage increased urine output significantly more than placebo at 24 hours (P <or= .02), with the difference averaging 1.0 to 1.5 L. Decreases in mean body weight with conivaptan 40 and 80 mg/d ( approximately 1-2 kg) paralleled the increases in urine output but did not reach statistical significance. Conivaptan was well tolerated and not associated with clinically important changes in vital signs, electrolyte disturbances, or cardiac rhythm. The most common adverse events were infusion-site reactions.When added to standard therapy for ADHF, conivaptan safely improves urine output. Further study of this compound in ADHF may be warranted, especially in view of the limitations of current treatment for this syndrome." @default.
• W2103292074 created "2016-06-24" @default.
• W2103292074 creator A5012021200 @default.
• W2103292074 creator A5020953670 @default.
• W2103292074 creator A5039521418 @default.
• W2103292074 creator A5078541553 @default.
• W2103292074 creator A5080740886 @default.
• W2103292074 date "2008-10-01" @default.
• W2103292074 modified "2023-10-16" @default.
• W2103292074 title "Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study" @default.
• W2103292074 cites W1970134098 @default.
• W2103292074 cites W1972068155 @default.
• W2103292074 cites W1976197893 @default.
• W2103292074 cites W1981834831 @default.
• W2103292074 cites W1994690457 @default.
• W2103292074 cites W2004750897 @default.
• W2103292074 cites W2011628654 @default.
• W2103292074 cites W2016178054 @default.
• W2103292074 cites W2021967123 @default.
• W2103292074 cites W2030725425 @default.
• W2103292074 cites W2035376123 @default.
• W2103292074 cites W2058542276 @default.
• W2103292074 cites W2061977229 @default.
• W2103292074 cites W2075802816 @default.
• W2103292074 cites W2104871844 @default.
• W2103292074 cites W2112636786 @default.
• W2103292074 cites W2119875370 @default.
• W2103292074 cites W2135149679 @default.
• W2103292074 cites W2141703599 @default.
• W2103292074 cites W2164846898 @default.
• W2103292074 cites W2169560588 @default.
• W2103292074 cites W2586400969 @default.
• W2103292074 cites W3022559795 @default.
• W2103292074 cites W2409760414 @default.
• W2103292074 doi "https://doi.org/10.1016/j.cardfail.2008.06.003" @default.
• W2103292074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18926434" @default.
• W2103292074 hasPublicationYear "2008" @default.
• W2103292074 type Work @default.
• W2103292074 sameAs 2103292074 @default.
• W2103292074 citedByCount "93" @default.
• W2103292074 countsByYear W21032920742012 @default.
• W2103292074 countsByYear W21032920742013 @default.
• W2103292074 countsByYear W21032920742014 @default.
• W2103292074 countsByYear W21032920742015 @default.
• W2103292074 countsByYear W21032920742016 @default.
• W2103292074 countsByYear W21032920742017 @default.
• W2103292074 countsByYear W21032920742018 @default.
• W2103292074 countsByYear W21032920742019 @default.
• W2103292074 countsByYear W21032920742020 @default.
• W2103292074 countsByYear W21032920742021 @default.
• W2103292074 countsByYear W21032920742022 @default.
• W2103292074 countsByYear W21032920742023 @default.
• W2103292074 crossrefType "journal-article" @default.
• W2103292074 hasAuthorship W2103292074A5012021200 @default.
• W2103292074 hasAuthorship W2103292074A5020953670 @default.
• W2103292074 hasAuthorship W2103292074A5039521418 @default.
• W2103292074 hasAuthorship W2103292074A5078541553 @default.
• W2103292074 hasAuthorship W2103292074A5080740886 @default.
• W2103292074 hasConcept C126322002 @default.
• W2103292074 hasConcept C142724271 @default.
• W2103292074 hasConcept C159641895 @default.
• W2103292074 hasConcept C164705383 @default.
• W2103292074 hasConcept C170493617 @default.
• W2103292074 hasConcept C177713679 @default.
• W2103292074 hasConcept C197934379 @default.
• W2103292074 hasConcept C20352681 @default.
• W2103292074 hasConcept C204787440 @default.
• W2103292074 hasConcept C27081682 @default.
• W2103292074 hasConcept C2776370428 @default.
• W2103292074 hasConcept C2776885963 @default.
• W2103292074 hasConcept C2778198053 @default.
• W2103292074 hasConcept C2779295919 @default.
• W2103292074 hasConcept C2779547328 @default.
• W2103292074 hasConcept C71924100 @default.
• W2103292074 hasConceptScore W2103292074C126322002 @default.
• W2103292074 hasConceptScore W2103292074C142724271 @default.
• W2103292074 hasConceptScore W2103292074C159641895 @default.
• W2103292074 hasConceptScore W2103292074C164705383 @default.
• W2103292074 hasConceptScore W2103292074C170493617 @default.
• W2103292074 hasConceptScore W2103292074C177713679 @default.
• W2103292074 hasConceptScore W2103292074C197934379 @default.
• W2103292074 hasConceptScore W2103292074C20352681 @default.
• W2103292074 hasConceptScore W2103292074C204787440 @default.
• W2103292074 hasConceptScore W2103292074C27081682 @default.
• W2103292074 hasConceptScore W2103292074C2776370428 @default.
• W2103292074 hasConceptScore W2103292074C2776885963 @default.
• W2103292074 hasConceptScore W2103292074C2778198053 @default.
• W2103292074 hasConceptScore W2103292074C2779295919 @default.
• W2103292074 hasConceptScore W2103292074C2779547328 @default.
• W2103292074 hasConceptScore W2103292074C71924100 @default.
• W2103292074 hasIssue "8" @default.
• W2103292074 hasLocation W21032920741 @default.
• W2103292074 hasLocation W21032920742 @default.
• W2103292074 hasOpenAccess W2103292074 @default.
• W2103292074 hasPrimaryLocation W21032920741 @default.
• W2103292074 hasRelatedWork W1858846670 @default.
• W2103292074 hasRelatedWork W2043757191 @default.
• W2103292074 hasRelatedWork W2048886386 @default.

• next